Get Your Personalized Supplement StackSupplement Stack Quiz

Lactobacillus Acidophilus Pxn 35

Also known as: Lactobacillus acidophilus PXN 35, L. acidophilus PXN 35, Lactobacillus acidophilus (strain PXN 35)

Overview

Lactobacillus acidophilus PXN 35 is a specific probiotic strain belonging to the *Lactobacillus acidophilus* species, a lactic acid bacterium naturally present in the human gastrointestinal tract and fermented foods. It is used to promote gut health by modulating the intestinal microbiota, improving digestion, and potentially alleviating gastrointestinal disorders like irritable bowel syndrome (IBS) and diarrhea. This strain is often included in multi-strain probiotic formulations and has been studied in clinical trials targeting IBS symptoms and other digestive issues. While *L. acidophilus* as a species has been extensively researched, specific data on the PXN 35 strain are more limited and often found within multi-strain studies. The quality of evidence varies, with some systematic reviews highlighting strain-specific effects and the need for more targeted research. It is available in various forms, including capsules and powders, and is sourced through controlled fermentation processes.

Benefits

Lactobacillus acidophilus PXN 35, primarily in multi-strain formulations, has shown potential benefits in improving IBS symptoms, including reducing abdominal pain, bloating, and bowel irregularities. Studies have reported statistically significant symptom improvement compared to placebo in IBS patients, although effect sizes were moderate and varied by study. Some evidence suggests modest benefits in reducing diarrhea incidence, although meta-analyses indicate that the clinical significance of *L. acidophilus* probiotics for diarrhea treatment is limited. Secondary effects include enhancement of intestinal barrier function, modulation of immune responses, and competitive inhibition of pathogenic bacteria, contributing to overall gut health. Patients with IBS, particularly IBS-D, may experience symptom relief with probiotic supplementation including *L. acidophilus* PXN 35, with improvements observed over intervention periods ranging from 4 to 16 weeks.

How it works

Lactobacillus acidophilus PXN 35 exerts its probiotic effects through several mechanisms. It produces lactic acid, which lowers the intestinal pH and inhibits the growth of pathogenic bacteria. The strain competes with pathogens for adhesion sites on the intestinal mucosa, enhancing colonization resistance. Additionally, it modulates cytokine profiles, reducing inflammation and promoting immune tolerance. *L. acidophilus* PXN 35 also stimulates epithelial mucin production, strengthening the intestinal barrier. As a live bacterial probiotic, it colonizes the gut transiently; survival through gastric acid and bile is critical for efficacy and is strain-dependent.

Side effects

Lactobacillus acidophilus PXN 35 is generally regarded as safe for healthy individuals and patients with IBS or mild gastrointestinal disturbances. The most common side effects are mild gastrointestinal symptoms such as bloating or gas, which may occur in some individuals. Rare cases of infection have been reported in severely immunocompromised patients, but these are exceedingly uncommon. No significant drug interactions have been reported. Caution is advised in immunocompromised individuals or those with severe underlying illnesses. While generally safe in adults, the safety in pediatric and pregnant populations requires strain-specific safety data. It is important to note that while rare, probiotics, including *L. acidophilus* PXN 35, could potentially lead to systemic infections in highly susceptible individuals.

Dosage

Clinical trials with Lactobacillus acidophilus PXN 35 often use doses around 8 × 10^9 CFU daily, typically administered twice daily in capsule form. The minimum effective dose for PXN 35 alone has not been definitively established; however, multi-strain formulations containing similar doses have shown efficacy. It is usually administered with meals to enhance survival through gastric acid. Capsules or powders with guaranteed CFU counts are preferred for consistent dosing. While specific upper limits and safety thresholds for PXN 35 are not well-defined, it is advisable to adhere to the dosages used in clinical trials and to consult with a healthcare professional before exceeding these amounts.

FAQs

Is L. acidophilus PXN 35 effective alone or only in combination?

Most clinical evidence involves multi-strain probiotics including PXN 35; isolated effects require further study to determine if the benefits are strain-specific or due to synergistic effects with other strains.

How long before benefits are seen?

Symptom improvement in IBS may take 4–16 weeks of consistent use. Individual responses can vary, and it's important to maintain a consistent regimen to assess effectiveness.

Are there risks for healthy individuals?

Minimal risks are associated with *L. acidophilus* PXN 35 for healthy individuals; however, mild GI symptoms such as bloating or gas are possible initially as the gut microbiota adjusts.

Can it prevent diarrhea?

Current evidence does not support a significant preventive effect for all-cause diarrhea. Other probiotic strains or interventions may be more effective for diarrhea prevention.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC6769995/ – This systematic review of 7 RCTs involving IBS patients found that probiotic formulations including *L. acidophilus* PXN 35 significantly improved IBS symptoms compared to placebo, with moderate effect sizes. The review highlights the heterogeneity of strains and doses used in the studies and acknowledges that the use of multi-strain formulations limits the ability to draw strain-specific conclusions.
https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2022.983075/full – This systematic review and meta-analysis of 4 RCTs on *L. acidophilus* for diarrhea found no statistically significant or clinically meaningful benefit of *L. acidophilus* probiotics for diarrhea compared to placebo. The authors noted the small number of studies, the limitations of strain-specific data, and the clinical heterogeneity among the included trials.
https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2023.pdf – The World Gastroenterology Organisation guidelines provide a systematic review and expert consensus on probiotics, including *L. acidophilus*. The guidelines emphasize that probiotics, including *L. acidophilus*, can modulate gut immunity and barrier function, but also highlight that effects are strain- and dose-specific, and strain-specific data are often sparse.
https://www.mdpi.com/1422-0067/24/4/3081 – This study investigates the immunomodulatory effects of *Lactobacillus acidophilus*. It provides insights into how this probiotic strain interacts with the immune system, potentially contributing to its beneficial effects on gut health and overall well-being.
https://www.cureus.com/articles/73344-efficacy-of-probiotics-as-prophylaxis-for-urinary-tract-infections-in-premenopausal-women-a-systematic-review-and-meta-analysis – This systematic review and meta-analysis examines the efficacy of probiotics, including *Lactobacillus acidophilus*, as prophylaxis for urinary tract infections in premenopausal women. It assesses the potential of probiotics to prevent UTIs and provides insights into their role in maintaining urogenital health.